
    
      This study consists of 2 parts:

      Part A: Dose-escalation protocol using oligomeric gp160MN/LAI-2. Part B: Placebo-controlled,
      randomized, double-blind (within arm) study of vCP205 priming with gp160MN/LAI-2 boosting.

      Volunteers are followed for at least 1 year.
    
  